Loading stock data…
PRGO
$11.07-0.64 (-5.47%)
Market ClosedLast close May 11
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Perrigo Company plc in the Healthcare sector is trading at $11.07. The stock is currently near its 52-week low of $9.23, remaining 31.0% below its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why PRGO maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$11.07
Potential Upside
5%
Whystock Fair Value$11.62
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Buy
Mean target$16.50+49.1%
Range$14.00 – $20.00
Fundamentals
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper res...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.63B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.49
Div Yield
Strong income play. Yield provides a meaningful total return floor.
981.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.73%
Volume
Today's trading volume
1.80M
Recent News
Perrigo Q1 Earnings Surpass Estimates, Sales Miss, Both Fall Y/Y
PRGO beats Q1 EPS estimates despite lower sales. Weakness in cough and cold demand offsets gains in Women's Health and Infant Formula.
Assessing Perrigo (PRGO) Valuation After Weak Q1 Results And Lowered Guidance
Perrigo (PRGO) stock is in focus after the company reported first quarter sales of US$969.2 million and a net loss of US$398.6 million, which widened sharply from the prior year. See our latest analysis for Perrigo. The weak first quarter numbers and recent investigation headlines come after a difficult stretch for investors, with a 1 year total shareholder return of 50.36% and a 5 year total shareholder return of 67.42%. However, the recent 1 month share price return of 15.77% hints at short...
Perrigo Company plc Q1 2026 Earnings Call Summary
Moby summary of Perrigo Company plc's Q1 2026 earnings call
Perrigo (PRGO) Q1 Earnings Beat Estimates
Perrigo (PRGO) delivered earnings and revenue surprises of +10.26% and -4.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How Investors Are Reacting To Perrigo (PRGO) Dermacosmetics Sale, Dividend Payout, And Infant Formula Strains
Perrigo Company plc recently completed the sale of its branded Dermacosmetics business to Karo Healthcare for up to €332.6 million and affirmed a quarterly dividend of US$0.2900 per share payable on June 16, 2026. At the same time, Perrigo faces analyst pessimism, legal scrutiny, and operational challenges in its infant formula unit, raising questions about the durability of its current business reset. We’ll now explore how mounting concerns around Perrigo’s infant formula segment may...